Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorHamilton Health Sciences Corporation
About this trial
Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
Eligibility criteria
Qualifiers
Age ≥18 years
Provide informed consent to participate.
Disqualifiers
Currently treated with and cannot withdraw colchicine due to medical necessity; or
Known allergy/sensitivity to colchicine; or
Prior self-reported intolerance to colchicine at a dose of 0.6 mg daily or lower; or
Currently pregnant or planning to become pregnant or breastfeed during the study; or
Trial design
Treatments tested in this trial
- Colchicine
Treatment groups
200 Participants
are divided into 2 treatment groupsLocations
3University of Alberta HospitalT6G 2B7, EdmontonAlberta, Canada
St. Joseph's Healthcare HamiltonL8N 4A6, HamiltonOntario, Canada
London Health Sciences CentreN6A 5A5, LondonOntario, Canada
Sponsors and collaborators
Hamilton Health Sciences Corporation
Lead sponsor
Hamilton Academic Health Sciences Organization
Collaborator
St. Joseph's Health Care London
Collaborator
Source ClinicalTrials.gov